44 results on '"Corvaglia, S"'
Search Results
2. Application of Recycled Carbon Fibers in Aircraft Windows Frame
- Author
-
Minosi, S., primary, Buccoliero, G., additional, Araganese, M., additional, Raganato, U., additional, Tarzia, A., additional, Corvaglia, S., additional, and Gallo, N., additional
- Published
- 2023
- Full Text
- View/download PDF
3. PREDICTORS OF CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS: CORRELATION BETWEEN THE PRESENCE OF CARDIOVASCULAR DISEASE AND CHARACTERISTICS OF THE JOINT DISEASE
- Author
-
Borghi, C., Bentivenga, C., Cicero, A.F., Trevisani, M., Rossi, E., Viviani, F., Maranini, B., Mulè, R., Vukatana, G., Buffa, A., Corvaglia, S., and Malavolta, N.
- Published
- 2019
- Full Text
- View/download PDF
4. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy
- Author
-
Migliaccio, S., Francomano, D., Romagnoli, E., Marocco, C., Fornari, R., Resmini, G., Buffa, A., Di Pietro, G., Corvaglia, S., Gimigliano, F., Moretti, A., de Sire, A., Malavolta, N., Lenzi, A., Greco, E. A., and Iolascon, G.
- Published
- 2017
- Full Text
- View/download PDF
5. AB0725 Scleroderma study group Emilia Romagna (Sclero-RER): real life use of prostacyclin analog. Preliminary data from a multicentric survey.
- Author
-
Magnani, L., primary, Ariani, A., additional, Girelli, F., additional, Spinella, A., additional, Lumetti, F., additional, Lo Monaco, A., additional, Reta, M., additional, Arrigoni, E., additional, Ursini, F., additional, Bezzi, A., additional, Cataleta, P., additional, Montaguti, L., additional, Trevisani, M., additional, Colina, M., additional, Bernardi, S., additional, Becciolini, A., additional, Galoppini, G., additional, Pignataro, F., additional, Ciaffi, J., additional, Bravi, E., additional, Focherini, M. C., additional, Moscatelli, S., additional, Sambo, P., additional, Mule’, R., additional, Corvaglia, S., additional, Bajocchi, G., additional, Conti, D., additional, Salvarani, C., additional, and Giuggioli, D., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Chondroma of the tongue
- Author
-
Scivetti, M., Maiorano, E., Pietro Pilolli, G., Corvaglia, S., Cimmino, M. A., Lucchese, A., and Favia, G.
- Published
- 2008
7. Development and First Validation of a Disease Activity Score for Gout
- Author
-
Scire, C, Carrara, G, Viroli, C, Cimmino, M, Taylor, W, Manara, M, Govoni, M, Salaffi, F, Punzi, L, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Scire C. A., Carrara G., Viroli C., Cimmino M. A., Taylor W. J., Manara M., Govoni M., Salaffi F., Punzi L., Montecucco C., Matucci-Cerinic M., Minisola G., Ariani A., Galossi A., Lauriti C., Fracassi E., Idolazzi L., Bardelli M., Selvi E., Tirri E., Furini F., Inverardi F., Calabro A., Porta F., Bittelli R., Venturino F., Capsoni F., Prevete I., Sebastiani G., Selmi C., Fabbriciani G., D'Avola G., Botticella G., Serale F., Seminara G., D'Alessandro G., Santo L., Longato L., Zaccara E., Sinigaglia L., Atteritano M., Broggini M., Caprioli M., Favero M., Salli S., Scarati M., Parisi S., Malavolta N., Corvaglia S., Scarpato S., Veneto V., Scire, C, Carrara, G, Viroli, C, Cimmino, M, Taylor, W, Manara, M, Govoni, M, Salaffi, F, Punzi, L, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Scire C. A., Carrara G., Viroli C., Cimmino M. A., Taylor W. J., Manara M., Govoni M., Salaffi F., Punzi L., Montecucco C., Matucci-Cerinic M., Minisola G., Ariani A., Galossi A., Lauriti C., Fracassi E., Idolazzi L., Bardelli M., Selvi E., Tirri E., Furini F., Inverardi F., Calabro A., Porta F., Bittelli R., Venturino F., Capsoni F., Prevete I., Sebastiani G., Selmi C., Fabbriciani G., D'Avola G., Botticella G., Serale F., Seminara G., D'Alessandro G., Santo L., Longato L., Zaccara E., Sinigaglia L., Atteritano M., Broggini M., Caprioli M., Favero M., Salli S., Scarati M., Parisi S., Malavolta N., Corvaglia S., Scarpato S., and Veneto V.
- Abstract
Objective: To develop a new composite disease activity score for gout and provide its first validation. Methods: Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results: Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion: This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.
- Published
- 2016
8. Out-of-Autoclave Repair of Composite Laminates by Using Shape Memory Polymer Foams
- Author
-
Bellisario, D., primary, Quadrini, F., additional, Santo, L., additional, Iorio, L., additional, Gallo, N., additional, and Corvaglia, S., additional
- Published
- 2019
- Full Text
- View/download PDF
9. X-RAY PHOTOELECTRON SPECTROSCOPY AS A NEW TOOL TO STUDY THE INTERACTION BETWEEN CELLS AND INORGANIC NANOPARTICLES
- Author
-
RELLA, SIMONA, TURCO, ANTONIO, POMPA, Pier Paolo, MALITESTA, Cosimino, Corvaglia, S., Moglianetti, M., Rella, Simona, Turco, Antonio, Corvaglia, S., Moglianetti, M., Pompa, Pier Paolo, and Malitesta, Cosimino
- Published
- 2016
10. Development and first validation of a disease activity score for gout
- Author
-
Scirè, Ca1, Carrara, G2, Viroli, C3, Cimmino, Ma4, Taylor, Wj5, Manara, M2, Govoni, M6, Salaffi, F7, Punzi, L8, Montecucco, C9, Matucci Cerinic M10, Minisola, G11, Collaborators Ariani A, Study Group for the Kick Off of the Italian Network for Gout S. t. u. d. y., Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabrò, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, Marco, Broggini, M, Caprioli, M, Favero, M, Sallì, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V., Scire, C, Carrara, G, Viroli, C, Cimmino, M, Taylor, W, Manara, M, Govoni, M, Salaffi, F, Punzi, L, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Scirè, Carlo A, Carrara, Greta, Viroli, Cinzia, Cimmino, Marco A., Taylor, William J., Manara, Maria, Govoni, Marcello, Salaffi, Fausto, Punzi, Leonardo, Montecucco, Carlomaurizio, Matucci-Cerinic, Marco, Minisola, Giovanni, Ariani, Alarico, Galossi, Alessandra, Lauriti, Ciro, Fracassi, Elena, Idolazzi, Luca, Bardelli, Marco, Selvi, Enrico, Tirri, Enrico, Furini, Federica, Inverardi, Flora, Calabrò, Andrea, Porta, Francesco, Bittelli, Raffaele, Venturino, Francesco, Capsoni, Franco, Prevete, Immacolata, Sebastiani, Giandomenico, Selmi, Carlo, Fabbriciani, Gianluigi, D'Avola, Giovanni, Botticella, Giulia, Serale, Francesca, Seminara, Giulia, D'Alessandro, Giuseppe, Santo, Leonardo, Longato, Lorena, Zaccara, Eleonora, Sinigaglia, Luigi, Atteritano, Marco, Broggini, Marco, Caprioli, Marta, Favero, Marta, Sallì, Salvatore, Scarati, Marco, Parisi, Simone, Malavolta, Nazzarena, Corvaglia, Stefania, Scarpato, Salvatore, and Veneto, Vittorio
- Subjects
Male ,medicine.medical_specialty ,Visual analogue scale ,Aged ,Arthralgia ,Factor Analysis, Statistical ,Female ,Follow-Up Studies ,Gout ,Humans ,Joints ,Linear Models ,Middle Aged ,Pain Measurement ,Patient Reported Outcome Measures ,Regression Analysis ,Reproducibility of Results ,Uric Acid ,Disease Progression ,Severity of Illness Index ,NO ,disease activity, gout, patient perspective ,03 medical and health sciences ,0302 clinical medicine ,gout ,Rheumatology ,Discriminant function analysis ,Linear regression ,Criterion validity ,medicine ,030212 general & internal medicine ,030203 arthritis & rheumatology ,business.industry ,Construct validity ,Regression analysis ,Statistical ,medicine.disease ,Linear discriminant analysis ,patient perspective ,Physical therapy ,Rheumatology, Factor Analysis ,business ,Factor Analysis ,disease activity - Abstract
Objective To develop a new composite disease activity score for gout and provide its first validation. Methods Disease activity has been defined as the ongoing presence of urate deposits that lead to acute arthritis and joint damage. Every measure for each Outcome Measures in Rheumatology core domain was considered. A 3-step approach (factor analysis, linear discriminant analysis, and linear regression) was applied to derive the Gout Activity Score (GAS). Decision to change treatment or 6-month flare count were used as the surrogate criteria of high disease activity. Baseline and 12-month followup data of 446 patients included in the Kick-Off of the Italian Network for Gout cohort were used. Construct- and criterion-related validity were tested. External validation on an independent sample is reported. Results Factor analysis identified 5 factors: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA). Discriminant function analysis resulted in a correct classification of 79%. Linear regression analysis identified a first candidate GAS including 12-month flare count, sUA, visual analog scale (VAS) of pain, VAS global activity assessment, swollen and tender joint counts, and a cumulative measure of tophi. Alternative scores were also developed. The developed GAS demonstrated a good correlation with functional disability (criterion validity) and discrimination between patient- and physician-reported measures of active disease (construct validity). The results were reproduced in the external sample. Conclusion This study developed and validated a composite measure of disease activity in gout. Further testing is required to confirm its generalizability, responsiveness, and usefulness in assisting with clinical decisions.
- Published
- 2016
11. Lifestyle and dietary habits of patients with gout followed in rheumatology settings
- Author
-
Manara, M, Carrara, G, Scire, C, Cimmino, M, Govoni, M, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Manara M., Carrara G., Scire C. A., Cimmino M. A., Govoni M., Montecucco C., Matucci-Cerinic M., Minisola G., Ariani A., Galossi A., Lauriti C., Fracassi E., Idolazzi L., Bardelli M., Selvi E., Tirri E., Furini F., Inverardi F., Calabro A., Porta F., Bittelli R., Venturino F., Capsoni F., Prevete I., Sebastiani G., Selmi C., Fabbriciani G., D'Avola G., Botticella G., Serale F., Seminara G., D'Alessandro G., Santo L., Longato L., Zaccara E., Sinigaglia L., Atteritano M., Broggini M., Caprioli M., Favero M., Salli S., Scarati M., Parisi S., Malavolta N., Corvaglia S., Scarpato S., Veneto V., Manara, M, Carrara, G, Scire, C, Cimmino, M, Govoni, M, Montecucco, C, Matucci-Cerinic, M, Minisola, G, Ariani, A, Galossi, A, Lauriti, C, Fracassi, E, Idolazzi, L, Bardelli, M, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Calabro, A, Porta, F, Bittelli, R, Venturino, F, Capsoni, F, Prevete, I, Sebastiani, G, Selmi, C, Fabbriciani, G, D'Avola, G, Botticella, G, Serale, F, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Zaccara, E, Sinigaglia, L, Atteritano, M, Broggini, M, Caprioli, M, Favero, M, Salli, S, Scarati, M, Parisi, S, Malavolta, N, Corvaglia, S, Scarpato, S, Veneto, V, Manara M., Carrara G., Scire C. A., Cimmino M. A., Govoni M., Montecucco C., Matucci-Cerinic M., Minisola G., Ariani A., Galossi A., Lauriti C., Fracassi E., Idolazzi L., Bardelli M., Selvi E., Tirri E., Furini F., Inverardi F., Calabro A., Porta F., Bittelli R., Venturino F., Capsoni F., Prevete I., Sebastiani G., Selmi C., Fabbriciani G., D'Avola G., Botticella G., Serale F., Seminara G., D'Alessandro G., Santo L., Longato L., Zaccara E., Sinigaglia L., Atteritano M., Broggini M., Caprioli M., Favero M., Salli S., Scarati M., Parisi S., Malavolta N., Corvaglia S., Scarpato S., and Veneto V.
- Abstract
Diet and lifestyles modification are core aspects of the non-pharmacological management of gout, but a poor consistency with suggested guidelines is reported. This study aimed to investigate dietary and lifestyle habits of patients with gout followed in rheumatology settings. Data were retrieved from the baseline dataset of the KING study, a multicentre cohort study of patients with gout followed in rheumatology settings. Dietary habits were assessed with the Italian National Institute of Statistics (ISTAT) food-frequency questionnaire and compared with reported data about general population. The relative increase of exposure was estimated by standardized prevalence ratios adjusted for gender, age and geographical distribution. The study population included 446 patients, with a mean age of 63.9 years and a M/F ratio of 9:1. Compared to the Italian population, gouty patients showed a higher prevalence of obesity [1.82 (1.52-2.18)] and a higher consumption of wine [1.85 (1.48-2.32)] and beer [2.21 (1.68-2.90)], but a lower prevalence of smoking and a lower intake of liquor. They showed a lower intake of red meat [0.80 (0.71-0.91)], but a similar intake of other tested dietary factors. Gouty patients’ lifestyle is still partially different from the recommended.
- Published
- 2015
12. Chitin whiskers reinforced carrageenan films as low adhesion cell substrates
- Author
-
Corvaglia, S., Rodríguez, S., Bardi, G., Torres, F. G., López García, Daniel, Corvaglia, S., Rodríguez, S., Bardi, G., Torres, F. G., and López García, Daniel
- Abstract
Carrageenan was used to prepare carrageenan films reinforced with chitin nanowhiskers. Atomic force microscopy was used to characterize the morphology and roughness of the films. Structural characterization was performed using X-ray diffraction and Fourier transform infrared spectroscopy. The mechanical properties were assessed by tensile tests. The prepared nanocomposites were used as cell substrate in order to explore their potential biological applications. HeLa cells were seeded on the samples in order to assess their biocompatibility. The preliminary results show good cell proliferation but low cell adhesion, demonstrating a potential application of this novel material as substrate for tumor cell culture.
- Published
- 2016
13. Efficacia della terapia sistemica con Idrossiclorochina solfato (Plaquenil) sulla superficie oculare di pazienti affetti da Sindrome di Sjogren's primaria
- Author
-
VERSURA, PIERA, ERMINI, LAURA, MALAVOLTA, NAZZARENA, CAMPOS, EMILIO, Scarale ME, Vukatana G, Corvaglia S, Versura P, Scarale ME, Vukatana G, Corvaglia S, Ermini L, Malavolta N, and Campos E
- Subjects
Idrossiclorochina solfato ,Sindrome di Sjogren' ,Dry Eye ,superficie oculare - Published
- 2011
14. Cirrosi biliare primitiva: una sindrome paraneoplastica
- Author
-
Cardella G, Bentivenga C, Tartagni E, Pombeni M, Rinaldi ER, Corvaglia S, Ermini L, COSENTINO, EUGENIO ROBERTO, BORGHI, CLAUDIO, Cardella G, Bentivenga C, Cosentino ER, Tartagni E, and Pombeni M, Rinaldi ER, Corvaglia S, Ermini L, Borghi C
- Published
- 2009
15. Uno strano caso di miopatia
- Author
-
Pombeni M, Bentivenga C, Rinaldi ER, Corvaglia S, Brusi V, Santi F, Tartagni E, BORGHI, CLAUDIO, Pombeni M, Bentivenga C, Rinaldi ER, Corvaglia S, Brusi V, Santi F, Tartagni E, and Borghi C
- Published
- 2009
16. L'intterpretazione critica degli studi ONTARGET e TRASCEND: un esempio di eseprienza clinica applicata alle veidenze
- Author
-
BORGHI, CLAUDIO, Corvaglia S., Borghi C, and Corvaglia S.
- Abstract
Interpretazione critica dei trials clinici nell'ambito della valutazione del rischio cardiovascolare globale.
- Published
- 2009
17. Chondroma of the tongue: a case report
- Author
-
SCIVETTI M, MAIORANO E, PILOLLI GP, CORVAGLIA S, CIMMINO MA, FAVIA G., LUCCHESE, Alberta, Scivetti, M, Maiorano, E, Pilolli, Gp, Corvaglia, S, Cimmino, Ma, Lucchese, Alberta, and Favia, G.
- Published
- 2008
18. Oral-facial lesions in two patients with Rendu-Osler-Weber sindrome
- Author
-
LUCCHESE, Alberta, CORVAGLIA S, SCIVETTI M, DE FALCO V, SERPICO, Rosario, GRASSI R, FAVIA G., Lucchese, Alberta, Corvaglia, S, Scivetti, M, DE FALCO, V, Serpico, Rosario, Grassi, R, and Favia, G.
- Published
- 2006
19. FRI0330 Predictivity of Ocular Surface Parameters and Tear Protein Expression in The Diagnosis of Sjögren Syndrome versus Dry Eye
- Author
-
Vukatana, G., primary, Versura, P., additional, Trevisani, M., additional, Giannaccare, P., additional, Buffa, A., additional, Mulè, R., additional, Corvaglia, S., additional, Rossi, E., additional, and Malavolta, N., additional
- Published
- 2016
- Full Text
- View/download PDF
20. SAT0317 Correlation Between Serum Uric Acid and Left Ventricular Mass in Essential Hypertension
- Author
-
Rinaldi, E.R., primary, Bentivenga, C., additional, Cosentino, E., additional, Corvaglia, S., additional, Rosticci, M., additional, Magnani, L., additional, Ricci Iamino, I., additional, Cicero, A.F., additional, Malavolta, N., additional, and Borghi, C., additional
- Published
- 2015
- Full Text
- View/download PDF
21. Immunological properties of Andean starch films are independent of their nanometric roughness and stiffness
- Author
-
Torres, F.G., primary, Troncoso, O.P., additional, Gamucci, O., additional, Corvaglia, S., additional, Brunetti, V., additional, and Bardi, G., additional
- Published
- 2015
- Full Text
- View/download PDF
22. Molecularly imprinted polypyrrole for the electrochemical detection of sulfadimethoxine: The effect of imprinting parameters
- Author
-
Mazzotta, E., primary, Turco, A., additional, Malitesta, C., additional, and Corvaglia, S., additional
- Published
- 2014
- Full Text
- View/download PDF
23. AB0216 Activation of the renin angiotensin sistem in a population of patients with rheumatoid arthritis and low severity comorbidity in therapy with dmards and/or anti-tnf alfha
- Author
-
Bentivenga, C., primary, Rinaldi, E. R., additional, Santi, F., additional, Cosentino, E., additional, Corvaglia, S., additional, Vukatana, G., additional, Malavolta, N., additional, and Borghi, C., additional
- Published
- 2013
- Full Text
- View/download PDF
24. AB0632 Efficacy of hydroxychloroquine therapy on whole salivary components in patients with primary sjogren’s syndrome
- Author
-
Corvaglia, S., primary, Vukatana, G., additional, Ermini, L., additional, Versura, P., additional, Coslovi, C., additional, Campos, E., additional, Gavaruzzi, G., additional, and Malavolta, N., additional
- Published
- 2013
- Full Text
- View/download PDF
25. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR)
- Author
-
Carlo, Scirè, Maria, Manara, Marco, Cimmino, Marcello, Govoni, Fausto, Salaffi, Leonardo, Punzi, Maria, Monti, Greta, Carrara, Carlomaurizio, Montecucco, Marco Matucci Cerinic, Giovanni Minisola Collaborators Galossi, A, Lauriti, C, Fracassi, E, Selvi, E, Tirri, E, Furini, F, Inverardi, F, Porta, F, Venturino, F, Capsoni, F, Sebastiani, G, Fabbriciani, G, Botticella, G, Seminara, G, D'Alessandro, G, Santo, L, Longato, L, Sinigaglia, L, Atteritano, Marco, Broggini, M, Caprioli, M, Favero, M, Sallì, S, Parisi, S, Corvaglia, S, Veneto, V., Scire', C, Manara, M, Cimmino, M, Govoni, M, Salaffi, F, Punzi, L, Monti, M, Carrara, G, Montecucco, C, Matucci Cerinic, M, Minisola, G, and Collaborators, K
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Cross-sectional study ,Health Status ,Immunology ,Population ,Comorbidity ,NO ,Cohort Studies ,Disability Evaluation ,gout ,Rheumatology ,Quality of life ,Risk Factors ,Surveys and Questionnaires ,Internal medicine ,Outcome Assessment, Health Care ,health related quality of life ,medicine ,Humans ,Immunology and Allergy ,Registries ,education ,Aged ,education.field_of_study ,business.industry ,Odds ratio ,Middle Aged ,medicine.disease ,humanities ,Gout ,Cross-Sectional Studies ,Italy ,quality of life ,Physical therapy ,Female ,business ,Research Article ,Cohort study - Abstract
Introduction: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in patients with gout followed in rheumatology clinics.Methods: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy. Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores (PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals.Results: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1% showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81). Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and corticosteroid treatment (-3.39 [-5.30,-1.48]).Conclusions: The data from the KING study confirm that gout impacts on disability and provide evidence for an independent association of gout and gout-related features with functional outcome and HRQoL. This result supports the need to improve specific treatment in gout.
- Published
- 2013
- Full Text
- View/download PDF
26. Blockchain Technology based on Algorand applied to low-power and low-cost IoT devices
- Author
-
Teodoro Montanaro, Luigi Patrono, Luca Mainetti, Andrea Palmieri, Beatrice Rossi, Antonio Vilei, Salvatore Corvaglia, Ilaria Sergi, SpliTech 2021, Montanaro, T., Sergi, I., Corvaglia, S., Mainetti, L., Vilei, A., Palmieri, A., Rossi, B., and Patrono, L.
- Subjects
Blockchain ,business.industry ,Smart objects ,Computer science ,Data security ,Computer security ,computer.software_genre ,Raspberry pi ,Power (social and political) ,Scalability ,IoT, Blockchain, Algorand, Raspberry Pi, STM32MP157A-DK1 ,Internet of Things ,business ,computer - Abstract
Thanks to the ever-increasing number of connected, innovative and smart objects that have been adopted since now in almost every sector, the Internet of Things is transforming people lives. Nonetheless, one of the major challenges encountered by practitioners and experts every day is related to cybersecurity and the need of protecting collected information at all the levels of IoT ecosystems. Unfortunately, also due to the growing number of connected devices, data security has become extremely complex. One of the revolutionary technologies that has the potential to address such needs and, also, support privacy and scalability is the Blockchain. Among the various existing Blockchains present in literature and in the market, Algorand is emerging as one of the most promising technologies for the IoT due to its intrinsic self-sustaining and decentralized nature. This paper discusses preliminary results obtained in the adoption of the Algorand Blockchain in two of the most spread low-powered IoT devices such as the Raspberry Pi 4 Model B and the STMicroelectronics STM32MP157A-DK1.
- Published
- 2021
27. An innovative and simple all electrochemical approach to functionalize electrodes with a carbon nanotubes/polypyrrole molecularly imprinted nanocomposite and its application for sulfamethoxazole analysis
- Author
-
Pier Paolo Pompa, Antonio Turco, Stefania Corvaglia, Cosimino Malitesta, Turco, A., Corvaglia, S., Pompa, P. P., and Malitesta, C.
- Subjects
Materials science ,Sulfamethoxazole ,Polymers ,Electrode ,Overoxidized polypyrrole ,02 engineering and technology ,Carbon nanotube ,010402 general chemistry ,Electrosynthesis ,Electrochemistry ,Polypyrrole ,Pyrrole ,01 natural sciences ,Electrosynthesi ,Nanocomposites ,law.invention ,Biomaterials ,Molecular Imprinting ,chemistry.chemical_compound ,Colloid and Surface Chemistry ,law ,Limit of Detection ,Humans ,Pyrroles ,Polymer ,Electrodes ,Detection limit ,Molecularly imprinted polymer ,Nanocomposite ,Electrochemical Technique ,Nanotubes, Carbon ,Electrochemical Techniques ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,Chemical engineering ,chemistry ,0210 nano-technology ,Human - Abstract
Sulfamethoxazole (SMX) is a commonly used antibiotic which accumulation can favor the development of antimicrobial resistance. Therefore, easy and cheap system to monitor the presence of SMX are needed for human health protection. Herein we present a straightforward all electrochemical approach to fabricate a sensor based on a nanocomposite molecularly imprinted polymer (nanoMIP) for the determination of SMX. Firstly, oxidized multiwalled carbon nanotubes (oxMWCNTs) were electrochemically deposited on a polarized electrode to increase electrodic surface area up to 350%. Then, ultrathin overoxidized polypyrrole MIP in presence of SMX was electropolymerized on oxMWCNTs surface (nanoMIP). Finally, antibiotic was electrochemically removed. The obtained nanoMIP was characterized by atomic force microscopy, X-ray photoelectron spectroscopy and electrochemical techniques. The nanoMIP was used for the electrochemical detection of SMX evidencing a lower limit of detection (413 nM) and a wider linear range (1.99–10.88 μM) with respect a non-nanostructured film. The nanoMIP evidenced also good affinity and a highly reproducible response (RSD = 1.2%). The sensor was able to determine SMX in milk samples evidencing good recovery values. The proposed approach can be also used in future to easily prepare different nanoMIP based sensors with improved performances for different target molecules thus overcoming current fabrication limits.
- Published
- 2021
28. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy
- Author
-
Silvia Migliaccio, Rachele Fornari, Francesca Gimigliano, Giovanni Iolascon, Emanuela A. Greco, G. Di Pietro, S. Corvaglia, Giuseppina Resmini, Chiara Marocco, Nazzarena Malavolta, Davide Francomano, Elisabetta Romagnoli, Antimo Moretti, Andrea Lenzi, A. Buffa, A. de Sire, Migliaccio, S, Francomano, D., Romagnoli, E., Marocco, C., Fornari, R., Resmini, G., Buffa, A., Di Pietro, G., Corvaglia, S., Gimigliano, Francesca, Moretti, A., de Sire, A., Malavolta, N., Lenzi, A., Greco, E. A., and Iolascon, Giovanni
- Subjects
medicine.medical_specialty ,Pediatrics ,Bone density ,Endocrinology, Diabetes and Metabolism ,Osteoporosis ,030209 endocrinology & metabolism ,Medication Adherence ,Persistence ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Bone Density ,Observational study ,medicine ,Humans ,030212 general & internal medicine ,Medical prescription ,Osteoporosis, Postmenopausal ,Femoral neck ,Aged ,Bone Density Conservation Agents ,business.industry ,Therapeutic effect ,Osteoporosi ,Middle Aged ,medicine.disease ,Prognosis ,medicine.anatomical_structure ,Denosumab ,Fracture ,Italy ,Physical therapy ,Female ,business ,Body mass index ,Osteoporotic Fractures ,medicine.drug ,Follow-Up Studies - Abstract
Background: Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. Aim: The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. Material/subjects and methods: Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia ® ) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m 2 . At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was −2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was −2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. Conclusions: Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures. Background: Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. Aim: The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. Material/subjects and methods: Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia®) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m2. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was −2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was −2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. Conclusions: Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures.
- Published
- 2017
29. Microenvironmental Stiffness of 3D Polymeric Structures to Study Invasive Rates of Cancer Cells
- Author
-
Barbara Spagnolo, Ferruccio Pisanello, Enrico Domenico Lemma, Francesco Rizzi, Marco Pisanello, Stefania Corvaglia, Massimo De Vittorio, Lemma, Enrico Domenico, Spagnolo, Barbara, Rizzi, Francesco, Corvaglia, Stefania, Pisanello, Marco, De Vittorio, Massimo, Pisanello, Ferruccio, Lemma, E. D., Spagnolo, B., Rizzi, F., Corvaglia, S., Pisanello, M., De Vittorio, M., and Pisanello, F.
- Subjects
0301 basic medicine ,Scaffold ,Materials science ,Polymers ,Mechanical Phenomena ,Biomedical Engineering ,Pharmaceutical Science ,Nanotechnology ,Cell Communication ,02 engineering and technology ,Multiphoton lithography ,Biomaterials ,Extracellular matrix ,invasivene ,03 medical and health sciences ,Cell Movement ,Cell Line, Tumor ,Elastic Modulus ,Cell Adhesion ,medicine ,Humans ,Neoplasm Invasiveness ,Cell adhesion ,stiffne ,cancer cell ,technology, industry, and agriculture ,Stiffness ,Hydrogels ,021001 nanoscience & nanotechnology ,Biomaterial ,Extracellular Matrix ,030104 developmental biology ,Self-healing hydrogels ,Cancer cell ,mechanosensing ,two-photon lithography ,medicine.symptom ,0210 nano-technology - Abstract
Cells are highly dynamic elements, continuously interacting with the extracellular environment. Mechanical forces sensed and applied by cells are responsible for cellular adhesion, motility, and deformation, and are heavily involved in determining cancer spreading and metastasis formation. Cell/extracellular matrix interactions are commonly analyzed with the use of hydrogels and 3D microfabricated scaffolds. However, currently available techniques have a limited control over the stiffness of microscaffolds and do not allow for separating environmental properties from biological processes in driving cell mechanical behavior, including nuclear deformability and cell invasiveness. Herein, a new approach is presented to study tumor cell invasiveness by exploiting an innovative class of polymeric scaffolds based on two-photon lithography to control the stiffness of deterministic microenvironments in 3D. This is obtained by fine-tuning of the laser power during the lithography, thus locally modifying both structural and mechanical properties in the same fabrication process. Cage-like structures and cylindric stent-like microscaffolds are fabricated with different Young's modulus and stiffness gradients, allowing obtaining new insights on the mechanical interplay between tumor cells and the surrounding environments. In particular, cell invasion is mostly driven by softer architectures, and the introduction of 3D stiffness “weak spots” is shown to boost the rate at which cancer cells invade the scaffolds. The possibility to modulate structural compliance also allowed estimating the force distribution exerted by a single cell on the scaffold, revealing that both pushing and pulling forces are involved in the cell–structure interaction. Overall, exploiting this method to obtain a wide range of 3D architectures with locally engineered stiffness can pave the way for unique applications to study tumor cell dynamics. © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
- Published
- 2017
- Full Text
- View/download PDF
30. P751 EVALUATION OF DENOSUMAB PERSISTENCE IN POSTMENOPAUSAL WOMEN AFFECTED BY SEVERE OSTEOPOROSIS: A MULTICENTER OBSERVATIONAL REAL PRACTICE STUDY
- Author
-
S. Migliaccio, D. Francomano, E. Romagnoli, C. Marocco, R. Fornari, G. Resmini, A. Buffa, G. Di Pietro5, S. Corvaglia, F. Gimigliano, MORETTI A, A. de Sire, N. Malavolta, A. Lenzi, E. A. Greco, G. Iolascon, Migliaccio, S., Francomano, D., Romagnoli, E., Marocco, C., Fornari, R., Resmini, G., Buffa, A., Di Pietro5, G., Corvaglia, S., Gimigliano, F., Moretti, A, de Sire, A., Malavolta, N., Lenzi, A., Greco, E. A., and Iolascon, G.
- Abstract
Objective: To evaluate persistence to denosumab treatment in osteoporotic postmenopausal women. Material and Methods: In this multicenter observational real practice study we recruited postmenopausal women affected by osteoporosis. We included women aged >50 years, able to receive a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were evaluated at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. Results: Eight hundred seventy women (with a mean age of 70 years and a mean body mass index of 24.8±4.1 kg/m2) were enrolled. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was -2.76±1.14 standard deviations (SD) and the mean femoral neck T-score was - 2.49±0.80 SD. During the study, the persistence was 91.4% and the total dropouts were 75 (8.6%). After 12 months of treatment, persistence to therapy was over 99%that was maintained during all the study. The 4% of study population, who had started earlier therapy, reached 56 months of treatment with a persistence of 100%. Conclusion: This multicenter observational real practice study showed that persistence to denosumab treatment in our cohort of postmenopausal women was very high. High persistence to therapy could be particularly linked to the pharmacological schedule, but also to other factors such as frequency of visits, and opportunity to call the doctor could play a role in the persistence to treatment in these patients.
- Published
- 2017
31. Molecularly imprinted polypyrrole for the electrochemical detection of sulfadimethoxine: The effect of imprinting parameters
- Author
-
Antonio Turco, Cosimino Malitesta, Elisabetta Mazzotta, Stefania Corvaglia, Mazzotta, Elisabetta, Turco, Antonio, Malitesta, Cosimino, and Corvaglia, S.
- Subjects
chemistry.chemical_compound ,chemistry ,Chemical engineering ,medicine ,Organic chemistry ,Sulfadimethoxine ,Electrochemical detection ,Imprinting (psychology) ,Polypyrrole ,medicine.drug - Published
- 2014
- Full Text
- View/download PDF
32. Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
- Author
-
Colina M, Khodeir M, Rimondini R, Valentini M, Campomori F, Corvaglia S, and Campana G
- Subjects
- Humans, Etanercept therapeutic use, Tumor Necrosis Factor-alpha, Adalimumab therapeutic use, Tumor Necrosis Factor Inhibitors therapeutic use, Retrospective Studies, Treatment Outcome, Infliximab, Antirheumatic Agents, Biosimilar Pharmaceuticals, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy
- Abstract
Background and Objectives: Long-term treatment of patients with rheumatoid arthritis with tumor necrosis factor-α inhibitors leads to initial changes in disease activity that can predict a late treatment response. This observational and retrospective study aimed to determine when it is possible to foresee the response to therapy in the case of long-standing rheumatoid arthritis comparing also the efficacy of the original biologics with their biosimilars., Methods: A total of 1598 patients were recruited and treated with the original biologics, adalimumab and etanercept, or with biosimilars. Patients were monitored over a period of 48 months and disease activity scores (28-Joint Disease Activity Score, Simplified Disease Activity Index, and Clinical Disease Activity Index) were measured every 6 months., Results: No differences in disease activity levels were observed in etanercept versus biosimilars (GP2015/SB4) and adalimumab versus biosimilar (GP2017) patient groups. All scores significantly decreased in all treatments during the first 18 months of therapy, and after 24 months reached a minimum that lasted up to 48 months., Conclusions: We conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor-α inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
- Author
-
Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I, Corvaglia S, Pedron MC, Mondin A, Iacobone M, Torresan F, Merante Boschin I, Bertazza L, Barollo S, Pennelli G, and Mian C
- Subjects
- Humans, Retrospective Studies, Proto-Oncogene Proteins c-ret genetics, Carcinoma, Medullary genetics, Carcinoma, Neuroendocrine genetics, Thyroid Neoplasms genetics
- Abstract
Background: The International Medullary Thyroid Carcinoma Grading System (IMTCGS) divides medullary thyroid carcinoma (MTC) into two categories, high- and low-grade tumors, which has a profound impact on patient outcomes. The aim of this study was to explore the association between IMTCGS grading, clinical data, and molecular status in sporadic MTC. Methods: A retrospective cohort study was performed on consecutive sporadic MTCs from patients undergoing initial surgery between January 2000 and January 2022 at the Padua Endocrine Surgery Unit. Clinical, pathological, and follow-up data were collected, tumors were graded, and somatic mutations of RET and RAS genes were analyzed. Patient outcomes were based on Ct levels and MTC-related deaths. Survival analyses were carried out employing the Kaplan-Meier method and the log-rank test. A Cox proportional hazard regression model was employed for multivariable survival analysis with the following covariates: somatic RET mutation, MTC stage at diagnosis, sex, age at diagnosis, and IMTCGS grade. Results: We included 141 consecutive sporadic MTCs. The median follow-up was 80.0 months (interquartile ranges: 41.5-122.5 months). Seventeen patients (12.1%) died from disease-related causes. 107/141 (76.9%) were classified as low-grade tumors, 32/141 (23.1%) as high-grade. Patients carrying a RET mutation had more aggressive features and shorter disease-specific survival (DSS) ( p = 0.001) and were more frequently classified high-grade than low-grade MTC ( p < 0.001). At multivariable survival analysis, only IMTCGS grading was independently associated with DSS (hazard ratio 8.8 [confidence interval: 2.7-28.3], p = 0.005). RET mutations, in particular RET -M918T, were more frequent in high-grade than in low-grade MTC (68.8% vs. 29.4% mutated in RET , 46.9% vs. 12.7% mutated in RET -M918T; p < 0.001). None of the high-grade tumors was mutated in the RAS gene, but the mutation was present in 11.8% of low-grade tumors. Conclusions: IMTCGS grading was associated with DSS independently of other clinical, pathological, and molecular factors. Moreover, MTC grading was associated with RET and RAS patterns, which explains, at least in part, the molecular basis of the aggressive behavior of high-grade MTC.
- Published
- 2024
- Full Text
- View/download PDF
34. Real life use of prostacyclin analog (iloprost), a multi-centric survey data from the Scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature.
- Author
-
Magnani L, Ariani A, Lo Monaco A, Girelli F, Spinella A, Lumetti F, Reta M, Arrigoni E, Ursini F, Bezzi A, Cataleta P, Montaguti L, Trevisani M, Colina M, Bernardi S, De Pinto M, Galoppini G, Testoni S, Becciolini A, Pignataro F, Ciaffi J, Bravi E, Focherini M, Moscatelli S, Sambo P, Fusconi M, Corvaglia S, Bajocchi G, Conti D, Salvarani C, and Giuggioli D
- Subjects
- Humans, Epoprostenol therapeutic use, Prostaglandins I, Wound Healing, Surveys and Questionnaires, Iloprost therapeutic use, Iloprost adverse effects, Scleroderma, Systemic drug therapy, Scleroderma, Systemic chemically induced
- Abstract
Background and Aim: Iloprost is recommend worldwide for the treatment of RP and the healing of DUs. The aim of this study is to report the regimens of Iloprost administered in different rheumatological centers within the same regional Health System Methods: A questionnaire exploring different items related to the use of Iloprost was developed and reviewed by three expert rheumatologists. The questionnaire was distributed as an online survey to all local SSc referral centers in Emilia-Romagna (Italy). Data are reported as percentage or median with interquartile range (IQR), as appropriate. An updated review of world literature on this topic was also carried out., Results: All the invited centers completed the survey. There were both local (8) and university hospitals (4). The majority (58%) had a rheumatologist as head physician. All centers used Iloprost: a single monthly administration was the most common treatment (75%). The cycle lasted 1 [IQR 1-2] days with a 0.5-2.0 ng/Kg/min dose according to the drug tolerance of the patients. There were overall 68 spots (beds, reclining armchair, or simple armchair); 2.0 [1.5-4.0] patients were able to receive Iloprost at the same time. University Hospitals had more physicians at their disposal than local hospitals but less paramedic personnel (respectively: 1.8 vs 1.2 physicians, 1.5 vs 2.1 nurses)., Conclusions: These observations were in line with the majority of previous studies reporting different regimens, comparing similar (but not identical) dose and schedule administration, however, despite differences being at times substantial, no standard infusion method is yet available.
- Published
- 2023
- Full Text
- View/download PDF
35. An innovative and simple all electrochemical approach to functionalize electrodes with a carbon nanotubes/polypyrrole molecularly imprinted nanocomposite and its application for sulfamethoxazole analysis.
- Author
-
Turco A, Corvaglia S, Pompa PP, and Malitesta C
- Subjects
- Electrochemical Techniques, Electrodes, Humans, Limit of Detection, Polymers, Pyrroles, Sulfamethoxazole, Molecular Imprinting, Nanocomposites, Nanotubes, Carbon
- Abstract
Sulfamethoxazole (SMX) is a commonly used antibiotic which accumulation can favor the development of antimicrobial resistance. Therefore, easy and cheap system to monitor the presence of SMX are needed for human health protection. Herein we present a straightforward all electrochemical approach to fabricate a sensor based on a nanocomposite molecularly imprinted polymer (nanoMIP) for the determination of SMX. Firstly, oxidized multiwalled carbon nanotubes (oxMWCNTs) were electrochemically deposited on a polarized electrode to increase electrodic surface area up to 350%. Then, ultrathin overoxidized polypyrrole MIP in presence of SMX was electropolymerized on oxMWCNTs surface (nanoMIP). Finally, antibiotic was electrochemically removed. The obtained nanoMIP was characterized by atomic force microscopy, X-ray photoelectron spectroscopy and electrochemical techniques. The nanoMIP was used for the electrochemical detection of SMX evidencing a lower limit of detection (413 nM) and a wider linear range (1.99-10.88 μM) with respect a non-nanostructured film. The nanoMIP evidenced also good affinity and a highly reproducible response (RSD = 1.2%). The sensor was able to determine SMX in milk samples evidencing good recovery values. The proposed approach can be also used in future to easily prepare different nanoMIP based sensors with improved performances for different target molecules thus overcoming current fabrication limits., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
36. Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data.
- Author
-
D'Angelo S, Gilio M, D'Attino RM, Gualberti G, Merolla R, di Luzio Paparatti U, Malavolta N, Corvaglia S, Marchetta A, Scambi C, Romeo N, Pettiti G, Salvarani C, Catanoso MG, Scarpa R, Costa L, Ramonda R, Frallonardo P, Muratore M, Quarta L, Passiu G, Erre GL, Lubrano D, Tirri E, Govoni M, Furini F, Russo R, Buono R, Pozzi MR, Riva M, Grembiale RD, Bruno C, Gibertini P, and Marchesoni A
- Subjects
- Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Young Adult, Antirheumatic Agents therapeutic use, Quality of Life, Spondylarthritis physiopathology, Spondylarthritis psychology, Spondylitis, Ankylosing physiopathology, Spondylitis, Ankylosing psychology
- Abstract
Objectives: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting., Methods: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA., Results: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup., Conclusions: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.
- Published
- 2019
37. Sputtering-Enabled Intracellular X-ray Photoelectron Spectroscopy: A Versatile Method To Analyze the Biological Fate of Metal Nanoparticles.
- Author
-
Turco A, Moglianetti M, Corvaglia S, Rella S, Catelani T, Marotta R, Malitesta C, and Pompa PP
- Subjects
- HeLa Cells, Humans, Oxidation-Reduction, Particle Size, Photoelectron Spectroscopy, Platinum metabolism, Silver metabolism, Surface Properties, Tumor Cells, Cultured, Metal Nanoparticles analysis, Platinum analysis, Silver analysis
- Abstract
The investigation of the toxicological profile and biomedical potential of nanoparticles (NPs) requires a deep understanding of their intracellular fate. Various techniques are usually employed to characterize NPs upon cellular internalization, including high-resolution optical and electron microscopies. Here, we show a versatile method, named sputtering-enabled intracellular X-ray photoelectron spectroscopy, proving that it is able to provide valuable information about the behavior of metallic NPs in culture media as well as within cells, directly measuring their internalization, stability/degradation, and oxidation state, without any preparative steps. The technique can also provide nanoscale vertical resolution along with semiquantitative information about the cellular internalization of the metallic species. The proposed approach is easy-to-use and can become a standard technique in nanotoxicology/nanomedicine and in the rational design of metallic NPs. Two model cases were investigated: silver nanoparticles (AgNPs) and platinum nanoparticles (PtNPs) with the same size and coating. We observed that, after 48 h incubation, intracellular AgNPs were almost completely dissolved, forming nanoclusters as well as AgO, AgS, and AgCl complexes. On the other hand, PtNPs were resistant to the harsh endolysosomal environment, and only some surface oxidation was detected after 48 h.
- Published
- 2018
- Full Text
- View/download PDF
38. Microenvironmental Stiffness of 3D Polymeric Structures to Study Invasive Rates of Cancer Cells.
- Author
-
Lemma ED, Spagnolo B, Rizzi F, Corvaglia S, Pisanello M, De Vittorio M, and Pisanello F
- Subjects
- Cell Adhesion physiology, Cell Communication physiology, Cell Line, Tumor, Cell Movement physiology, Elastic Modulus physiology, Extracellular Matrix chemistry, Extracellular Matrix physiology, Humans, Hydrogels chemistry, Mechanical Phenomena drug effects, Neoplasm Invasiveness pathology, Polymers chemistry
- Abstract
Cells are highly dynamic elements, continuously interacting with the extracellular environment. Mechanical forces sensed and applied by cells are responsible for cellular adhesion, motility, and deformation, and are heavily involved in determining cancer spreading and metastasis formation. Cell/extracellular matrix interactions are commonly analyzed with the use of hydrogels and 3D microfabricated scaffolds. However, currently available techniques have a limited control over the stiffness of microscaffolds and do not allow for separating environmental properties from biological processes in driving cell mechanical behavior, including nuclear deformability and cell invasiveness. Herein, a new approach is presented to study tumor cell invasiveness by exploiting an innovative class of polymeric scaffolds based on two-photon lithography to control the stiffness of deterministic microenvironments in 3D. This is obtained by fine-tuning of the laser power during the lithography, thus locally modifying both structural and mechanical properties in the same fabrication process. Cage-like structures and cylindric stent-like microscaffolds are fabricated with different Young's modulus and stiffness gradients, allowing obtaining new insights on the mechanical interplay between tumor cells and the surrounding environments. In particular, cell invasion is mostly driven by softer architectures, and the introduction of 3D stiffness "weak spots" is shown to boost the rate at which cancer cells invade the scaffolds. The possibility to modulate structural compliance also allowed estimating the force distribution exerted by a single cell on the scaffold, revealing that both pushing and pulling forces are involved in the cell-structure interaction. Overall, exploiting this method to obtain a wide range of 3D architectures with locally engineered stiffness can pave the way for unique applications to study tumor cell dynamics., (© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2017
- Full Text
- View/download PDF
39. Boosting the therapeutic efficiency of nanovectors: exocytosis engineering.
- Author
-
Corvaglia S, Guarnieri D, and Pompa PP
- Subjects
- A549 Cells, Antineoplastic Agents administration & dosage, Doxorubicin administration & dosage, HeLa Cells, Humans, MCF-7 Cells, Nanomedicine, Spheroids, Cellular drug effects, Drug Carriers, Exocytosis, Nanoparticles, Silicon Dioxide
- Abstract
In this work, we developed a new general strategy, which we named "exocytosis engineering", to strongly increase the intracellular persistence of nanocarriers and thus the effective dose of transported drugs. The strategy is based on the co-loading of a drug and an exocytosis inhibitor in the nanocarrier, to hinder the high tendency of cells to remove internalized nanocarriers, limiting the pharmacological efficiency of the nanoformulation. In particular, by using a well-known chemotherapeutic drug (doxorubicin) and an efficient exocytosis inhibitor (dimethilamyloride) co-loaded in mesoporous silica nanocarriers, we demonstrated a >6-fold increase in the intracellular dose of the drug (for the same administered dose), achieving a great improvement in its therapeutic action. A strong gain in the cytotoxic effect of the drug was, in fact, observed both in several tumor cell lines and in 3D tumor spheroids. The proposed approach is versatile and broadly applicable to several classes of nanocarriers and drugs, thus opening a fascinating outlook in nanomedicine.
- Published
- 2017
- Full Text
- View/download PDF
40. Easy fabrication of aligned PLLA nanofibers-based 2D scaffolds suitable for cell contact guidance studies.
- Author
-
Mohanraj J, Puzzi L, Capria E, Corvaglia S, Casalis L, Mestroni L, Sbaizero O, and Fraleoni-Morgera A
- Subjects
- Animals, Cell Adhesion drug effects, Cell Proliferation drug effects, Cell Survival drug effects, HeLa Cells, Humans, Mice, Microscopy, Electron, Scanning, NIH 3T3 Cells, Nanofibers toxicity, Nanofibers chemistry, Polyesters chemistry, Tissue Scaffolds chemistry
- Abstract
An easy, low-cost and fast wet processing-based method named ASB-SANS (Auxiliary Solvent-Based Sublimation-Aided NanoStructuring) has been used to fabricate poly(l-lactic acid) (PLLA) highly ordered and hierarchically organized 2D fibrillar patterns, with fiber widths between 40 and 500 nm and lengths exceeding tens of microns. A clear contact guidance effect of these nanofibrillar scaffolds with respect to HeLa and NIH-3T3 cells growth has been observed, on top of an overall good viability. For NIH-3T3 pronounced elongation of the cells was observed, as well as a remarkable ability of the patterns to guide the extension of pseudopodia. Moreover, SEM imaging revealed filopodia stemming from both sides of the pseudopodia and aligned with the secondary PLLA nanofibrous structures created by the ASB-SANS procedure. These results validate ASB-SANS as a technique capable to provide biocompatible 2D nanofibrillar patterns suitable for studying phenomena of contact guidance (and, more in general, the behavior of cells onto nanofibrous scaffolds), at very low costs and in an extremely easy way, accessible to virtually any laboratory., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
41. A DNA-based nano-immunoassay for the label-free detection of glial fibrillary acidic protein in multicell lysates.
- Author
-
Ganau M, Bosco A, Palma A, Corvaglia S, Parisse P, Fruk L, Beltrami AP, Cesselli D, Casalis L, and Scoles G
- Subjects
- Antibodies chemistry, Antibodies immunology, Antigens chemistry, Antigens immunology, Astrocytes immunology, Astrocytes pathology, Biomarkers chemistry, Glial Fibrillary Acidic Protein immunology, Glioma diagnosis, Humans, Microscopy, Atomic Force, DNA chemistry, Glial Fibrillary Acidic Protein isolation & purification, Glioma immunology, Immunoassay
- Abstract
We have developed a quantitative approach to eventually enable precise and multiplexing protein analysis of very small systems, down to a single or a few cells. Through DNA-directed immobilization of DNA-protein conjugates we immobilized antibodies specific for a certain protein of interest, on a complementary DNA nanoarray fabricated by means of nanografting, a nanolithography technique based on atomic force microscopy (AFM). The proof of concept was realized for glial fibrillary acidic protein (GFAP), a biomarker crucial in cell's differentiation of astrocytes, and functional to grade classification of gliomas, the most common of primary malignant brain tumors. The efficiency of the nano-immuno sensing was tested by obtaining the immobilization of purified recombinant GFAP protein at different concentration in a standard solution then in a cellular lysate. A comparison of sensitivity between our technique and conventional ELISA assays is provided at the end of the paper., From the Clinical Editor: This team developed a quantitative approach to enable precise and multiplexing protein analysis of very small systems, down to a single or a few cells, demonstrating the utility of this DNA-based nano-immunoassay in the detection of GFAP., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
42. Electrochemical sensor for sulfadimethoxine based on molecularly imprinted polypyrrole: study of imprinting parameters.
- Author
-
Turco A, Corvaglia S, and Mazzotta E
- Subjects
- Anti-Bacterial Agents analysis, Anti-Bacterial Agents chemistry, Equipment Design, Equipment Failure Analysis, Reproducibility of Results, Sensitivity and Specificity, Sulfadimethoxine chemistry, Surface Properties, Conductometry instrumentation, Molecular Imprinting methods, Polymers chemistry, Pyrroles chemistry, Sulfadimethoxine analysis
- Abstract
The present work describes the development of a simple and cost-effective electrochemical sensor for sulfadimethoxine (SDM) based on molecularly imprinted overoxidized polypyrrole (PPy). An all electrochemical approach is used for sensor fabrication and application consisting in molecularly imprinted polymer (MIP) galvanostatic deposition on a gold electrode and its overoxidation under different experimental conditions and in SDM amperometric detection. Several parameters influencing the imprinting effect are critically discussed and evaluated. A key role of the electrolyte used in electropolymerization (tetrabuthylammonium perchlorate and lithium perchlorate) has emerged demonstrating its effect on sensing performances of imprinted PPy and, related to this, on its morphology, as highlighted by atomic force microscopy (AFM). The effect of different overoxidation conditions in removing template is evaluated by analyzing MIP films before and after the treatment by X-ray photoelectron spectroscopy (XPS) also evidencing the correlation between MIP chemical structure and its rebinding ability. MIP-template interaction is verified also by Fourier Transform Infrared (FT-IR) spectroscopy. Under the selected optimal conditions, MIP sensor shows a linear range from 0.15 to 3.7 mM SDM, a limit of detection of 70 μM, a highly reproducible response (RSD 4.2%) and a good selectivity in the presence of structurally related molecules. SDM was determined in milk samples spiked at two concentration levels: 0.2 mM and 0.4 mM obtaining a satisfactory recovery of (97±3)% and (96±8)%, respectively., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. Atomic force microscopy based nanoassay: a new method to study α-Synuclein-dopamine bioaffinity interactions.
- Author
-
Corvaglia S, Sanavio B, Hong Enriquez RP, Sorce B, Bosco A, Scaini D, Sabella S, Pompa PP, Scoles G, and Casalis L
- Subjects
- Adsorption, Binding Sites, Gold chemistry, Protein Binding, Sensitivity and Specificity, Dopamine chemistry, Metal Nanoparticles chemistry, Microscopy, Atomic Force methods, Nanotechnology methods, Protein Interaction Mapping methods, alpha-Synuclein chemistry
- Abstract
Intrinsically Disordered Proteins (IDPs) are characterized by the lack of well-defined 3-D structure and show high conformational plasticity. For this reason, they are a strong challenge for the traditional characterization of structure, supramolecular assembly and biorecognition phenomena. We show here how the fine tuning of protein orientation on a surface turns useful in the reliable testing of biorecognition interactions of IDPs, in particular α-Synuclein. We exploited atomic force microscopy (AFM) for the selective, nanoscale confinement of α-Synuclein on gold to study the early stages of α-Synuclein aggregation and the effect of small molecules, like dopamine, on the aggregation process. Capitalizing on the high sensitivity of AFM topographic height measurements we determined, for the first time in the literature, the dissociation constant of dopamine-α-Synuclein adducts.
- Published
- 2014
- Full Text
- View/download PDF
44. Defined α-synuclein prion-like molecular assemblies spreading in cell culture.
- Author
-
Aulić S, Le TT, Moda F, Abounit S, Corvaglia S, Casalis L, Gustincich S, Zurzolo C, Tagliavini F, and Legname G
- Subjects
- Animals, Cell Line, Humans, Mice, Macromolecular Substances metabolism, Neurons metabolism, Prions classification, Prions metabolism, alpha-Synuclein classification, alpha-Synuclein metabolism
- Abstract
Background: α-Synuclein (α-syn) plays a central role in the pathogenesis of synucleinopathies, a group of neurodegenerative disorders that includes Parkinson disease, dementia with Lewy bodies and multiple system atrophy. Several findings from cell culture and mouse experiments suggest intercellular α-syn transfer., Results: Through a methodology used to obtain synthetic mammalian prions, we tested whether recombinant human α-syn amyloids can promote prion-like accumulation in neuronal cell lines in vitro. A single exposure to amyloid fibrils of human α-syn was sufficient to induce aggregation of endogenous α-syn in human neuroblastoma SH-SY5Y cells. Remarkably, endogenous wild-type α-syn was sufficient for the formation of these aggregates, and overexpression of the protein was not required., Conclusions: Our results provide compelling evidence that endogenous α-syn can accumulate in cell culture after a single exposure to exogenous α-syn short amyloid fibrils. Importantly, using α-syn short amyloid fibrils as seed, endogenous α-syn aggregates and accumulates over several passages in cell culture, providing an excellent tool for potential therapeutic screening of pathogenic α-syn aggregates.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.